JP2024527576A5 - - Google Patents
Info
- Publication number
- JP2024527576A5 JP2024527576A5 JP2024500409A JP2024500409A JP2024527576A5 JP 2024527576 A5 JP2024527576 A5 JP 2024527576A5 JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024500409 A JP2024500409 A JP 2024500409A JP 2024527576 A5 JP2024527576 A5 JP 2024527576A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- monoclonal antibody
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219175P | 2021-07-07 | 2021-07-07 | |
| US63/219,175 | 2021-07-07 | ||
| PCT/IB2022/000409 WO2023281313A1 (en) | 2021-07-07 | 2022-07-06 | Anti-tnfr2 antibody and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527576A JP2024527576A (ja) | 2024-07-25 |
| JP2024527576A5 true JP2024527576A5 (https=) | 2025-07-18 |
Family
ID=84800439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500409A Pending JP2024527576A (ja) | 2021-07-07 | 2022-07-06 | 抗ｔｎｆｒ２抗体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4367140A4 (https=) |
| JP (1) | JP2024527576A (https=) |
| KR (1) | KR20240032985A (https=) |
| CN (1) | CN117980336A (https=) |
| AR (1) | AR126387A1 (https=) |
| AU (1) | AU2022308421A1 (https=) |
| CA (1) | CA3224693A1 (https=) |
| TW (1) | TW202309096A (https=) |
| WO (1) | WO2023281313A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3256751A1 (en) * | 2022-05-26 | 2023-11-30 | Pfizer Inc. | Anti-TNFR2 antibodies and their methods of use |
| WO2024233258A1 (en) * | 2023-05-05 | 2024-11-14 | Cureimmune Therapeutics Inc. | Anti-tnfr2 antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190135929A1 (en) * | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| EP3707163A4 (en) * | 2017-11-09 | 2021-08-18 | The General Hospital Corporation | POLYPEPTIDES ANTAGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| EP3853252A1 (en) * | 2018-09-18 | 2021-07-28 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| CA3131953A1 (en) * | 2019-03-01 | 2020-09-10 | Merrimack Pharmaceuticals, Inc. | Anti-tnfr2 antibodies and uses thereof |
| WO2021023098A1 (zh) * | 2019-08-02 | 2021-02-11 | 江苏先声药业有限公司 | 抗tnfr2抗体及其用途 |
| CA3154643A1 (en) * | 2019-09-17 | 2021-03-25 | Apexigen, Inc. | Anti-tnfr2 antibodies and methods of use |
| CN112480259B (zh) * | 2021-02-05 | 2021-05-04 | 百奥赛图(北京)医药科技股份有限公司 | 抗tnfr2抗体及其用途 |
-
2022
- 2022-07-06 CN CN202280060055.4A patent/CN117980336A/zh active Pending
- 2022-07-06 JP JP2024500409A patent/JP2024527576A/ja active Pending
- 2022-07-06 AR ARP220101767A patent/AR126387A1/es unknown
- 2022-07-06 CA CA3224693A patent/CA3224693A1/en active Pending
- 2022-07-06 AU AU2022308421A patent/AU2022308421A1/en active Pending
- 2022-07-06 TW TW111125395A patent/TW202309096A/zh unknown
- 2022-07-06 EP EP22837100.1A patent/EP4367140A4/en active Pending
- 2022-07-06 KR KR1020247004535A patent/KR20240032985A/ko active Pending
- 2022-07-06 WO PCT/IB2022/000409 patent/WO2023281313A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Development of therapeutic antibodies for the treatment of diseases | |
| KR102068600B1 (ko) | Pdl-1 항체, 그 약학적 조성물 및 그 용도 | |
| JP7844558B2 (ja) | リンパ球における阻害経路の中和 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| TWI771361B (zh) | 人程序性死亡受體pd-1的單株抗體及其片段 | |
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2022526764A5 (https=) | ||
| JP2021531764A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2021515565A5 (https=) | ||
| JP2021516973A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| JP2020520370A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2010504755A5 (https=) | ||
| JP2024518947A (ja) | Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン | |
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2024528682A (ja) | 薬物組成物及び用途 | |
| CN112351794A (zh) | 用于尿路上皮癌的免疫治疗方法 | |
| WO2021115303A1 (zh) | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| CN111094339A (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2025511288A (ja) | 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用 | |
| JP2024527576A5 (https=) | ||
| JP2023517794A5 (https=) |